title: Lapatinib: an oral dual tyrosine kinase inhibitor for HER-2-positive breast cancer.
abstract: Breast cancer is the most common form of cancer and the second leading cause of cancer deaths among women in the USA. A quarter of all newly diagnosed cases are characterized by overexpression of HER-2 which is associated with poor prognosis. In March 2007, lapatinib, an oral dual-tyrosine kinase inhibitor was approved in combination with capecitabine for metastatic HER-2-positive breast cancer that has progressed on prior trastuzumab therapy, and in combination with letrozole for postmenopausal women with HER-2 and hormone receptor-positive advanced breast cancer. In the future, lapatinib may play an important role in dual HER-2 blockade with trastuzumab and other targeted agents for women with HER-2-overexpressing breast cancer.
authors.affiliation: Indiana University Melvin & Bren Simon Cancer Center, Indianapolis, IN 46202, USA.
authors.forename: Sagar D
authors.initials: SD
authors.lastname: Sardesai
authors.affiliation: Indiana University Melvin & Bren Simon Cancer Center, Indianapolis, IN 46202, USA.
authors.forename: Anna Maria
authors.initials: AM
authors.lastname: Storniolo
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics; D005260:Female; D006801:Humans; D000077341:Lapatinib; D017698:Postmenopause; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*; D018719:Erb-b2 Receptor Tyrosine Kinases; D014481:United States; D016387:Women's Health
chemical_list: D000970:Antineoplastic Agents; D000077341:Lapatinib; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human
keywords: ERBB2; GW572016; HER-2; capecitabine; lapatinib; letrozole; metastatic breast cancer; trastuzumab